HER2 testing in the UK: Recommendations for breast and gastric in-situ hybridisation methods

Journal of Clinical Pathology

Volumn 64, Issue 8, 2011, Pages 649-653

  Bartlett, John M S ^a,b,c   Starczynski, J ^d   Atkey, Neil ^e   Kay, E ^f   O'Grady, A ^f   Gandy, Michael ^b   Ibrahim, Merdol ^b   Jasani, Bharat ^g   Ellis, I O ^h   Pinder, S E ⁱ   Walker, R A ^j  

^a Endocrine Cancer Group   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^f BEAUMONT HOSPITAL   (Ireland)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h Department of Pathology ^*  (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ASPIRATION BIOPSY; BREAST CANCER; CANCER GROWTH; CHROMOSOME 17; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEDICAL AUDIT; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STAFF TRAINING; STOMACH CANCER; TISSUE MICROARRAY; TURNAROUND TIME;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; INSERVICE TRAINING; MEDICAL STAFF; MOLECULAR PROBE TECHNIQUES; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; RECEPTOR, ERBB-2; RESEARCH DESIGN; SPECIMEN HANDLING; STOMACH NEOPLASMS;

EID: 79960707969     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2011.089847     Document Type: Review

References (22)

1. Sauter G, Lee J, Bartlett JMS, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
2. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol 2008;130:920-6.
3. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Path 2008;61:818-24. (Pubitemid 351969725)
4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
5. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 2010;457:299-307.
6. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-8. (Pubitemid 38955532)
7. Tubbs R, Pettay J, Hicks D, et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 2004;35:589-94. (Pubitemid 41404644)
8. Bartlett JM, Campbell FM, Ibrahim M, et al. Chromogenic in situ hybridization a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol 2009;132:514-20.
9. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000;53:890-2.
10. Ellis IO, Bartlett J, Dowsett M, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7. (Pubitemid 38338829)
11. Bartlett JM, Ibrahim M, Jasani B, et al. External quality assurance schemes: the impact of participation in the UK versus rest of the world: 5 year data from the UK national external quality assurance scheme. Canc Res 2009;69(Suppl 1):826S.
12. Bartlett JM, Ibrahim M, Jasani B, et al. External quality assurance of HER2 FISH and ISH testing three years of the UK national external quality assurance scheme. Am J Clin Pathol 2009;131:106-11.
13. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007;16:207-10. (Pubitemid 350196977)
14. Bartlett JM, Campbell FM, Ibrahim M, et al. A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH. Histopathology 2010;56:297-304.
15. Bartlett JM, Campbell FM, Ibrahim M, et al. A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech (TM) HER2 FISH probe. Canc Res 2009;69(Suppl 1):206S.
16. Dowsett M, Ellis IO, Bartlett JMS, et al. Correlation between immunohistochemistry and FISH for HER-2 in 441 breast carcinomas from multiple hospitals. J Pathol 2001;195:5A.
17. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23. (Pubitemid 36411217)
18. Thomas JS. Quality assurance in Her-2 testing-redefining the gold standard. Clin Chem 2009;55:1265-7.
19. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92. (Pubitemid 47050838)
20. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J Clin Oncol 2005;23:2469-76. (Pubitemid 47050837)
21. Watters AD, Bartlett JMS. Fluorescence in situ hybridization in paraffin tissue sections - pretreatment protocol. Mol Biotechnol 2002;21:217-20. (Pubitemid 34680871)
22. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-14. (Pubitemid 36197611)